$LENZ
LENZ Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$4.07
▼-1.47%-$0.061
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateLENZ Therapeutics, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is LENZ down today? It is at $4.07 (-1.47%), and our scanner flagged it 47 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment LENZ spikes, and full due diligence on LENZ — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $LENZ 47 times in the last 30 days. Create a free account to track $LENZ, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on LENZ from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for LENZ today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystLENZ Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filingSC 13G/APassive 5%+ stake updatedSep 8, 2026 · 12 days ago| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Chevallard Daniel R. Officer | Bought (open market) | +8K 0.02% of company | added 100% | 13K | $64K at $8.57 | Mar 27, 26 |
Schimmelpennink Evert B. Officer | Bought (open market) | +28K 0.09% of company | added 57% | 77K | $251K at $8.95 | Mar 27, 26 |
George Jeffrey P. Director | Bought (open market) | +6K 0.02% of company | n/a | 6K | $50K at $8.92 | Mar 27, 26 |
Olsson Shawn Officer | Sold (automatic/other) | -10K 0.03% of company | sold 68% | 5K | $257K at $25.74 | Nov 17, 25 |
Olsson Shawn Officer | Other | 10K 0.03% of company | added 100% | 15K | $21K at $2.08 | Nov 17, 25 |
Chevallard Daniel R. Officer | Bought (open market) | +2K | added 69% | 5K | $50K at $22.71 | Nov 7, 25 |
Mccollum James W Director | Bought (open market) | +11K 0.03% of company | n/a | 11K | $239K at $22.79 | Nov 7, 25 |
Versant Venture Capital Vi, L.P. Beneficial Owner (10%) | Sold (automatic/other) | -133K 0.4% of company | sold 11% | 1.05M | $6.0M at $45.35 | Sep 30, 25 |
Versant Venture Capital Vi, L.P. Beneficial Owner (10%) | Sold (automatic/other) | -92K 0.3% of company | sold 5.4% | 1.61M | $4.2M at $45.35 | Sep 30, 25 |
Versant Venture Capital Vi, L.P. Beneficial Owner (10%) | Sold (automatic/other) | -91K 0.3% of company | sold 7.1% | 1.18M | $3.8M at $41.59 | Sep 18, 25 |
Versant Venture Capital Vi, L.P. Beneficial Owner (10%) | Sold (automatic/other) | -45K 0.1% of company | sold 2.6% | 1.70M | $1.9M at $41.59 | Sep 18, 25 |
Versant Venture Capital Vi, L.P. Beneficial Owner (10%) | Sold (automatic/other) | -47K 0.2% of company | sold 3.6% | 1.27M | $1.8M at $38.97 | Aug 26, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on LENZ from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for LENZ today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
LENZ last traded at $4.07, down 1.47% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
LENZ Therapeutics, Inc. Common Stock (LENZ) is next expected to report earnings on Wednesday, November 4, 2026, about 45 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The LENZ Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged LENZ 47 times in the last 30 days.
LENZ (LENZ Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $128M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge LENZ for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$LENZ discussion
Sign in to ask a question or join the discussion.